Early Progression of Diabetic Nephropathy Correlates With Methylglyoxal-Derived Advanced Glycation End Products
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Increased advanced glycation end products (AGEs) and oxidation products (OPs) are proposed to lead to progression of diabetic nephropathy (DN). We investigated the relationship between AGEs, OPs, and progression of DN in 103 subjects with type 1 diabetes participating in the Natural History of Diabetic Nephropathy Study. RESEARCH DESIGN AND METHODS: Mean age of subjects was 17.6 ± 7.4 years, and mean duration of diabetes was 8.3 ± 4.9 years. All patients were normoalbuminuric. Change in glomerular basement membrane (GBM) width from baseline to 5 years, measured using electron micrographs of renal biopsies, was our primary end point, and mesangial fractional volume was a secondary end point. Fast progressors (FPs) were defined as those in the upper quartile of GBM change, and the remaining patients were classified as slow progressors (SPs). AGEs (3-deoxyglucosone and methylglyoxal hydroimidazolones [MGHI]), carboxymethyl lysine (CML), carboxyethyl lysine (CEL), and OPs (methionine sulfoxide and 2-aminoadipic acid) were measured at year 5 by liquid chromatography/triple-quadruple mass spectroscopy on 10-K plasma filtrates. RESULTS: We found that MGHI, CEL, and CML levels were significantly higher in FPs relative to SPs. No product predicted mesangial expansion. A model containing only HbA1c accounted for 4.7% of GBM width variation, with the total variability explained by the model increasing to 11.6% when MGHI, CEL, and CML were added to the regression model (7.9% increase). MGHI was a significant independent predictor of FP. Using a logistic regression model to relate each biomarker to the probability of a subject’s classification as an FP, CML, CEL, and MGHI, but not HbA1c, showed a significant relationship to the probability of FP. CONCLUSIONS: The results suggest that these three major AGEs may be early indicators of progression of important DN lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Role of oxidative stress in diabetic complications: a new perspective on an old paradigm.
Baynes, J. W., & Thorpe, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.1 · Cited by 2,441 · cited 1×
“(31), however, it is possible that correlation of this AGE with GBM thickening also reflects some role for oxidative processes.”
BackgroundLachin, J. M., Genuth, S., Nathan, D. M., Zinman, B., Rutledge, B. N., & for the DCCT/EDIC Research Group (2008) · Diabetes · doi:10.2337/db07-1618 · Cited by 555
Postprandial Glucose Regulation and Diabetic Complications
Ceriello, A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2090 · Cited by 362
The Early Natural History of Nephropathy in Type 1 Diabetes
Steinke, J. M., Sinaiko, A. R., Kramer, M. S., Suissa, S., Chavers, B. M., Mauer, M., & for the International Diabetic Nephropathy Study Group (2005) · Diabetes · doi:10.2337/diabetes.54.7.2164 · Cited by 190
Self-citation
Cited by
Schalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Advanced glycation end products in the pathogenesis of chronic kidney disease
Rabbani, N., & Thornalley, P. J. (2018) · Kidney International · doi:10.1016/j.kint.2017.11.034 · Cited by 387
The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases
Maessen, D. E. M., Stehouwer, C. D. A., & Schalkwijk, C. G. (2015) · Clinical Science · doi:10.1042/cs20140683 · Cited by 334
Welsh, K. J., Kirkman, M. S., & Sacks, D. B. (2016) · Diabetes Care · doi:10.2337/dc15-2727 · Cited by 207
“This technique has been applied to a number of clinically important AGEs including pentosidine, CML, CEL, 3-deoxyglucosone, and methylglyoxal hydroimidazolones, and it has aided in the discovery of new candidate AGE products (67,85,86).”
MethodBrings, S., Fleming, T., Freichel, M., Muckenthaler, M., Herzig, S., & Nawroth, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050984 · Cited by 204
“In addition plasma levels of the AGE MG-H1 and another MG derived AGE, CEL discriminated between fast and slow progressors with diabetic nephropathy in patients with type 1 diabetes [78].”
BackgroundTakahashi, A., Takabatake, Y., Kimura, T., Maejima, I., Namba, T., Yamamoto, T., Matsuda, J., Minami, S., Kaimori, J.-Y., Matsui, I., et al. (2017) · Diabetes · doi:10.2337/db16-0397 · Cited by 122
Glyoxalase 1 Modulation in Obesity and Diabetes
Rabbani, N., & Thornalley, P. J. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7424 · Cited by 102
“Commoncomplicationsofdiabetesare:increased riskofCVD—CHD,peripheralarterydisease,andstroke;and microvascular complications—nephropathy, retinopathy, and neuropathy.”
InfluentialVitamin C supplementation for diabetes management: A comprehensive narrative review
Mason, S. A., Parker, L., van der Pligt, P., & Wadley, G. D. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.003 · Cited by 53
Metadata
- Authors
- Beisswenger, P. J., Howell, S. K., Russell, G. B., Miller, M. E., Rich, S. S., & Mauer, M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-09-14
- Volume
- 36
- Issue
- 10
- Pages
- 3234-3239
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2153819826
- Cited by
- 132
- References
- 6
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.